/**
 * Clinical Trials Data — Alexion Complement Inhibitor Landscape
 * Source: ClinicalTrials.gov v2 API (https://clinicaltrials.gov/api/v2/studies)
 * Fetched: 2026-02-23
 * All data is real and unmodified from the API response.
 */

// =============================================================================
// SOLIRIS (eculizumab) — Active Trials
// =============================================================================
export const TRIALS_SOLIRIS = [
  {
    nctId: 'NCT06452135',
    title: 'Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation',
    officialTitle: 'A Single Center, Open-label, Single-arm Study to Determine the Safety and Efficacy of a Single Dosing Regimen Eculizumab for Prevention of Antibody-Mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi-LDKTx)',
    status: 'NOT_YET_RECRUITING',
    phase: 'Phase 1/Phase 2',
    conditions: ['Kidney Transplantation'],
    interventions: ['Eculizumab'],
    sponsor: 'Tao Lin',
    startDate: '2024-07',
    completionDate: '2025-12',
    enrollment: 30,
    locationCount: 1,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07420296',
    title: 'Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder',
    officialTitle: 'Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Randomized Controlled Trial Study',
    status: 'RECRUITING',
    phase: 'Phase 4',
    conditions: ['Neuromyelitis Optica Spectrum Disorders (NMOSD)'],
    interventions: ['Eculizumab administration', 'High-dose corticosteroid pulse therapy', 'Plasma exchange (PE)'],
    sponsor: 'Tianjin Medical University General Hospital',
    startDate: '2026-01-01',
    completionDate: '2027-06-30',
    enrollment: 198,
    locationCount: 1,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT06724809',
    title: 'Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD',
    officialTitle: 'An Open-label, Single-arm, Multi-Center, Interventional Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adult Participants With Anti-Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders (NMOSD)',
    status: 'ACTIVE_NOT_RECRUITING',
    phase: 'Phase 3',
    conditions: ['NMOSD', 'Neuromyelitis Optica Spectrum Disorders'],
    interventions: ['eculizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-01-16',
    completionDate: '2026-12-07',
    enrollment: 21,
    locationCount: 7,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT04777435',
    title: 'Therapeutic Orientation Test in Thrombotic Microangiopathy',
    officialTitle: 'Therapeutic Orientation Test in Thrombotic Microangiopathy',
    status: 'RECRUITING',
    phase: null,
    conditions: ['Thrombotic Micro-angiopathy'],
    interventions: ['Therapeutic orientation test for TMA'],
    sponsor: 'University Hospital, Montpellier',
    startDate: '2021-04-03',
    completionDate: '2027-04-03',
    enrollment: 100,
    locationCount: 20,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07381205',
    title: 'Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)',
    officialTitle: 'Prospective Evaluation of Transplant Associated Thrombotic Microangiopathy (TA-TMA) Markers in a High-risk Cohort of Adults Undergoing Allogeneic Stem Cell Transplantation (SCT)',
    status: 'NOT_YET_RECRUITING',
    phase: null,
    conditions: ['Transplant Associated Microangiopathy TAM', 'Transplant Complication'],
    interventions: [],
    sponsor: 'Manuel Ricardo Espinoza-Gutarra',
    startDate: '2026-03-01',
    completionDate: '2028-10',
    enrollment: 85,
    locationCount: 1,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT06449001',
    title: 'Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis',
    officialTitle: 'A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria', 'PNH', 'Extravascular Hemolysis'],
    interventions: ['Danicopan'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-08-11',
    completionDate: '2028-03-10',
    enrollment: 6,
    locationCount: 4,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05646563',
    title: 'Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris',
    officialTitle: 'A Phase II, Open-Label Study of NM8074 in Soliris\u00ae-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)',
    status: 'NOT_YET_RECRUITING',
    phase: 'Phase 2',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['NM8074', 'Soliris'],
    sponsor: 'NovelMed Therapeutics',
    startDate: '2026-01',
    completionDate: '2028-01',
    enrollment: 12,
    locationCount: 0,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07154745',
    title: 'A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With PNH Whose Current Treatment is Not Working Efficiently',
    officialTitle: 'A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Pozelimab', 'Cemdisiran'],
    sponsor: 'Regeneron Pharmaceuticals',
    startDate: '2026-01-30',
    completionDate: '2031-07-25',
    enrollment: 35,
    locationCount: 2,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05805202',
    title: 'Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy',
    officialTitle: 'Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy',
    status: 'RECRUITING',
    phase: null,
    conditions: ['Atypical Hemolytic Uremic Syndrome'],
    interventions: ['Blood sampling and urine analysis'],
    sponsor: 'Mario Negri Institute for Pharmacological Research',
    startDate: '2023-05-03',
    completionDate: '2026-12-31',
    enrollment: 112,
    locationCount: 1,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05731050',
    title: 'Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)',
    officialTitle: 'A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)',
    status: 'NOT_YET_RECRUITING',
    phase: 'Phase 2',
    conditions: ['PNH - Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['NM8074'],
    sponsor: 'NovelMed Therapeutics',
    startDate: '2026-06',
    completionDate: '2028-03',
    enrollment: 6,
    locationCount: 0,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07010302',
    title: 'Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD',
    officialTitle: 'A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder',
    status: 'NOT_YET_RECRUITING',
    phase: 'Phase 4',
    conditions: ['NMOSD'],
    interventions: ['Rituximab (R)', 'Eculizumab (Soliris\u00ae)', 'Ravulizumab', 'Satralizumab', 'Inebilizumab'],
    sponsor: 'Massachusetts General Hospital',
    startDate: '2026-05',
    completionDate: '2030-05',
    enrollment: 160,
    locationCount: 3,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07413679',
    title: 'Long-term Safety of Danicopan: IPIG Registry-based Cohort Study',
    officialTitle: 'An Observational Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data',
    status: 'ACTIVE_NOT_RECRUITING',
    phase: null,
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria', 'PNH'],
    interventions: ['Danicopan'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-08-18',
    completionDate: '2029-07-01',
    enrollment: 50,
    locationCount: 1,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT04432584',
    title: 'A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With PNH Currently Treated With Complement Inhibitors',
    officialTitle: 'A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors',
    status: 'ACTIVE_NOT_RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Crovalimab', 'Eculizumab'],
    sponsor: 'Hoffmann-La Roche',
    startDate: '2020-09-30',
    completionDate: '2027-09-30',
    enrollment: 190,
    locationCount: 81,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07184840',
    title: 'Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder',
    officialTitle: 'Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder (NMOSD): a Multi-Center, Phase 2 Trial (EASE-NMO)',
    status: 'RECRUITING',
    phase: 'Phase 2',
    conditions: ['Neuromyelitis Optica Spectrum Disorder Attack'],
    interventions: ['Intravenous Methylprednisolone (IVMP)', 'Complement protein C5 inhibitor'],
    sponsor: 'Tianjin Medical University General Hospital',
    startDate: '2025-09-09',
    completionDate: '2026-12-31',
    enrollment: 110,
    locationCount: 1,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT06931691',
    title: 'A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China',
    officialTitle: 'A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan on Disease Management, Treatment-Related Outcomes and Healthcare Resource Utilization for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria in China',
    status: 'RECRUITING',
    phase: null,
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['LNP023'],
    sponsor: 'Novartis Pharmaceuticals',
    startDate: '2025-06-10',
    completionDate: '2027-04-20',
    enrollment: 80,
    locationCount: 9,
    studyType: 'OBSERVATIONAL',
  },
];

// =============================================================================
// ULTOMIRIS (ravulizumab) — Active Trials
// =============================================================================
export const TRIALS_ULTOMIRIS = [
  {
    nctId: 'NCT06333652',
    title: 'Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders',
    officialTitle: 'Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders',
    status: 'RECRUITING',
    phase: 'Phase 2',
    conditions: ['Preeclampsia'],
    interventions: ['Ravulizumab'],
    sponsor: 'Mayo Clinic',
    startDate: '2026-03-01',
    completionDate: '2028-12-31',
    enrollment: 14,
    locationCount: 1,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07399730',
    title: 'Ravulizumab Outcomes in Polish Patients With aHUS',
    officialTitle: 'A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome',
    status: 'NOT_YET_RECRUITING',
    phase: null,
    conditions: ['Atypical Hemolytic Uremic Syndrome'],
    interventions: ['Ravulizumab'],
    sponsor: 'AstraZeneca',
    startDate: '2026-04-01',
    completionDate: '2030-12-31',
    enrollment: 80,
    locationCount: 0,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT06449001',
    title: 'Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis',
    officialTitle: 'A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria', 'PNH', 'Extravascular Hemolysis'],
    interventions: ['Danicopan'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-08-11',
    completionDate: '2028-03-10',
    enrollment: 6,
    locationCount: 4,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07154745',
    title: 'A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With PNH Whose Current Treatment is Not Working Efficiently',
    officialTitle: 'A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Pozelimab', 'Cemdisiran'],
    sponsor: 'Regeneron Pharmaceuticals',
    startDate: '2026-01-30',
    completionDate: '2031-07-25',
    enrollment: 35,
    locationCount: 2,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT06877403',
    title: 'Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital',
    officialTitle: 'Prospective Study on the Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My" Asthenia',
    status: 'ENROLLING_BY_INVITATION',
    phase: null,
    conditions: ['Myasthenia Gravis'],
    interventions: [],
    sponsor: 'University Hospital, Clermont-Ferrand',
    startDate: '2025-01-31',
    completionDate: '2025-10',
    enrollment: 100,
    locationCount: 1,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT07010302',
    title: 'Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD',
    officialTitle: 'A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder',
    status: 'NOT_YET_RECRUITING',
    phase: 'Phase 4',
    conditions: ['NMOSD'],
    interventions: ['Rituximab (R)', 'Eculizumab (Soliris\u00ae)', 'Ravulizumab', 'Satralizumab', 'Inebilizumab'],
    sponsor: 'Massachusetts General Hospital',
    startDate: '2026-05',
    completionDate: '2030-05',
    enrollment: 160,
    locationCount: 3,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07413679',
    title: 'Long-term Safety of Danicopan: IPIG Registry-based Cohort Study',
    officialTitle: 'An Observational Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data',
    status: 'ACTIVE_NOT_RECRUITING',
    phase: null,
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria', 'PNH'],
    interventions: ['Danicopan'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-08-18',
    completionDate: '2029-07-01',
    enrollment: 50,
    locationCount: 1,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT05746559',
    title: 'ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE',
    officialTitle: 'ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study',
    status: 'ACTIVE_NOT_RECRUITING',
    phase: 'Phase 3',
    conditions: ['Chronic Kidney Disease', 'CKD', 'Cardiac Disease', 'Cardiopulmonary Bypass'],
    interventions: ['Placebo', 'Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2023-04-06',
    completionDate: '2027-02-17',
    enrollment: 736,
    locationCount: 164,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT04432584',
    title: 'A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With PNH Currently Treated With Complement Inhibitors',
    officialTitle: 'A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors',
    status: 'ACTIVE_NOT_RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Crovalimab', 'Eculizumab'],
    sponsor: 'Hoffmann-La Roche',
    startDate: '2020-09-30',
    completionDate: '2027-09-30',
    enrollment: 190,
    locationCount: 81,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT06830798',
    title: 'Ravulizumab in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation',
    officialTitle: 'A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Delayed Graft Function', 'DGF', 'Kidney Transplant'],
    interventions: ['Ravulizumab', 'Placebo'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-05-19',
    completionDate: '2028-11-06',
    enrollment: 450,
    locationCount: 129,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT07411963',
    title: 'Evaluation of Patients Receiving EARLY Ravulizumab Admitted in ICU for gMG Crisis',
    officialTitle: 'Evaluation of the Condition of Patients Receiving EARLY Treatment With Ravulizumab and Admitted in ICU for Generalized Myasthenia Gravis (gMG) Crisis : an Observational Prospective Multicentric Study in France',
    status: 'RECRUITING',
    phase: null,
    conditions: ['Myasthenia Gravis'],
    interventions: ['early use of Ravulizumab'],
    sponsor: 'Centre Hospitalier Universitaire de Nice',
    startDate: '2025-11-26',
    completionDate: '2027-06-01',
    enrollment: 30,
    locationCount: 1,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT07308574',
    title: 'Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS',
    officialTitle: 'Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome',
    status: 'RECRUITING',
    phase: 'Phase 4',
    conditions: ['aHUS', 'Atypical Hemolytic Uremic Syndrome'],
    interventions: ['Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-12-19',
    completionDate: '2027-06-25',
    enrollment: 20,
    locationCount: 12,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05133531',
    title: 'Pozelimab + Cemdisiran vs C5 Inhibitor in Complement Inhibitor Treatment-Naive PNH Patients',
    officialTitle: 'A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Ravulizumab', 'Pozelimab', 'Cemdisiran', 'Eculizumab'],
    sponsor: 'Regeneron Pharmaceuticals',
    startDate: '2022-08-01',
    completionDate: '2027-01-28',
    enrollment: 190,
    locationCount: 69,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05744921',
    title: 'Long-term Treatment With Pozelimab + Cemdisiran in Patients With PNH',
    officialTitle: 'An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria',
    status: 'RECRUITING',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Pozelimab', 'Cemdisiran'],
    sponsor: 'Regeneron Pharmaceuticals',
    startDate: '2023-03-07',
    completionDate: '2029-02-26',
    enrollment: 202,
    locationCount: 41,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT06967480',
    title: 'Early Ravulizumab Treatment Of Anti-AChR Antibody-Positive Generalized Myasthenia Gravis',
    officialTitle: 'MG-EVOLUTION. Early Ravulizumab Treatment Of Anti-AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis',
    status: 'RECRUITING',
    phase: null,
    conditions: ['Generalized Myasthenia Gravis', 'Anti-AChR Antibody Positive'],
    interventions: ['Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2025-07-31',
    completionDate: '2027-06-30',
    enrollment: 40,
    locationCount: 23,
    studyType: 'OBSERVATIONAL',
  },
];

// =============================================================================
// COMPETITOR TRIALS — Active
// =============================================================================
export const TRIALS_COMPETITORS = {
  // ---------------------------------------------------------------------------
  // Iptacopan (Novartis) — Factor B inhibitor
  // ---------------------------------------------------------------------------
  iptacopan: [
    {
      nctId: 'NCT04889430',
      title: 'Efficacy and Safety of Iptacopan in Adult Patients With aHUS Naive to Complement Inhibitor Therapy',
      officialTitle: 'A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Atypical Hemolytic Uremic Syndrome'],
      interventions: ['Iptacopan'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2022-01-17',
      completionDate: '2029-03-29',
      enrollment: 34,
      locationCount: 59,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT07229235',
      title: 'REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With PNH',
      officialTitle: 'REAL-CARE: Real-world Effectiveness of iptacopAn in itaLian Patients With Paroxysmal noCturnAl HemoglobinuRia: an Observational Study',
      status: 'NOT_YET_RECRUITING',
      phase: null,
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria (PNH)'],
      interventions: [],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2025-12-31',
      completionDate: '2028-08-31',
      enrollment: 50,
      locationCount: 0,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT06797518',
      title: 'Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN',
      officialTitle: 'A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care',
      status: 'RECRUITING',
      phase: 'Phase 2',
      conditions: ['Glomerulonephritis, IGA', 'Immunoglobulin A Nephropathy'],
      interventions: ['Iptacopan'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2025-02-21',
      completionDate: '2027-11-27',
      enrollment: 20,
      locationCount: 14,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06931691',
      title: 'Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China',
      officialTitle: 'A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan on Disease Management, Treatment-Related Outcomes and Healthcare Resource Utilization for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria in China',
      status: 'RECRUITING',
      phase: null,
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: ['LNP023'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2025-06-10',
      completionDate: '2027-04-20',
      enrollment: 80,
      locationCount: 9,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT03955445',
      title: 'Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN',
      officialTitle: 'An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Iptacopan (LNP023) in C3 Glomerulopathy or Idiopathic Immune-complex-membranoproliferative Glomerulonephritis',
      status: 'RECRUITING',
      phase: 'Phase 3',
      conditions: ['C3 Glomerulopathy', 'Immune-complex-membranoproliferative Glomerulonephritis'],
      interventions: ['LNP023'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2019-10-03',
      completionDate: '2036-05-30',
      enrollment: 225,
      locationCount: 49,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06903234',
      title: 'Post-authorization Safety Study of Iptacopan in Adult Patients With PNH Using IPIG PNH Registry',
      officialTitle: 'Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the Non-interventional IPIG PNH Registry',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: null,
      conditions: ['Hemoglobinuria, Paroxysmal'],
      interventions: ['Iptacopan'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2025-03-31',
      completionDate: '2029-10-01',
      enrollment: 200,
      locationCount: 1,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT04747613',
      title: 'Long-term Safety and Tolerability of Iptacopan in Patients With PNH',
      officialTitle: 'An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase 3 Studies With Iptacopan',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: ['Iptacopan'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2021-07-27',
      completionDate: '2027-10-19',
      enrollment: 208,
      locationCount: 57,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT07036718',
      title: 'Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice in the Russian Federation',
      officialTitle: 'A Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of Iptacopan in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) in Routine Clinical Practice in the Russian Federation',
      status: 'RECRUITING',
      phase: null,
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: [],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2025-07-28',
      completionDate: '2028-01-31',
      enrollment: 100,
      locationCount: 8,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT05935215',
      title: 'Switching From Anti-C5 Antibody to Iptacopan in Participants With aHUS',
      officialTitle: 'A Multicenter, Single Arm, Open-label Study to Evaluate Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With aHUS',
      status: 'RECRUITING',
      phase: 'Phase 3',
      conditions: ['Atypical Hemolytic Uremic Syndrome'],
      interventions: ['Iptacopan'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2024-02-28',
      completionDate: '2029-07-19',
      enrollment: 50,
      locationCount: 30,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT07331259',
      title: 'C3 Glomerulopathy Patient Characteristics and Treatment Response to Iptacopan in Routine Care (CHART-C3G)',
      officialTitle: 'C3 Glomerulopathy Patient Characteristics and Treatment Response to Iptacopan in Routine Care: Analysis of Medical Charts (CHART-C3G)',
      status: 'NOT_YET_RECRUITING',
      phase: null,
      conditions: ['C3 Glomerulopathy', 'Complement-mediated Kidney Disease', 'Proteinuria'],
      interventions: ['Iptacopan'],
      sponsor: 'Novartis Pharmaceuticals',
      startDate: '2026-01-01',
      completionDate: '2027-03-01',
      enrollment: 83,
      locationCount: 0,
      studyType: 'OBSERVATIONAL',
    },
  ],

  // ---------------------------------------------------------------------------
  // Pegcetacoplan (Apellis) — C3 inhibitor
  // ---------------------------------------------------------------------------
  pegcetacoplan: [
    {
      nctId: 'NCT07215390',
      title: 'APL 3007 + Pegcetacoplan in Geographic Atrophy Secondary to Age Related Macular Degeneration',
      officialTitle: 'A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration',
      status: 'RECRUITING',
      phase: 'Phase 2',
      conditions: ['Geographic Atrophy Secondary to Age-related Macular Degeneration'],
      interventions: ['APL-3007, pegcetacoplan (APL-2)', 'APL-3007, pegcetacoplan (APL-2)', 'Placebo, Syfovre'],
      sponsor: 'Apellis Pharmaceuticals, Inc.',
      startDate: '2025-06-23',
      completionDate: '2027-11',
      enrollment: 240,
      locationCount: 22,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06722157',
      title: 'BI 771716 Against Pegcetacoplan in Geographic Atrophy Secondary to AMD (VERDANT)',
      officialTitle: 'Randomized, Double-masked, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 2',
      conditions: ['Macular Degeneration, Age-related', 'Geographic Atrophy'],
      interventions: ['BI 771716', 'Pegcetacoplan', 'Sham comparator to BI 771716'],
      sponsor: 'Boehringer Ingelheim',
      startDate: '2025-01-06',
      completionDate: '2026-10-16',
      enrollment: 202,
      locationCount: 46,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04901936',
      title: 'Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)',
      officialTitle: 'An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria',
      status: 'RECRUITING',
      phase: 'Phase 2',
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria (PNH)', 'Paroxysmal Hemoglobinuria'],
      interventions: ['Pegcetacoplan'],
      sponsor: 'Apellis Pharmaceuticals, Inc.',
      startDate: '2021-02-04',
      completionDate: '2028-12',
      enrollment: 12,
      locationCount: 12,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04919629',
      title: 'APL-2 and Pembrolizumab vs Bevacizumab in Recurrent Ovarian Cancer',
      officialTitle: 'Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion',
      status: 'RECRUITING',
      phase: 'Phase 2',
      conditions: ['Recurrent Ovarian Carcinoma', 'Recurrent Fallopian Tube Carcinoma', 'Recurrent Primary Peritoneal Carcinoma'],
      interventions: ['Bevacizumab', 'Pegcetacoplan', 'Pembrolizumab'],
      sponsor: 'Roswell Park Cancer Institute',
      startDate: '2023-04-27',
      completionDate: '2027-04-30',
      enrollment: 60,
      locationCount: 1,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT03531255',
      title: 'Pegcetacoplan Long Term Safety and Efficacy Extension Study in PNH',
      officialTitle: 'An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['PNH'],
      interventions: ['Pegcetacoplan'],
      sponsor: 'Apellis Pharmaceuticals, Inc.',
      startDate: '2018-08-27',
      completionDate: '2025-06',
      enrollment: 160,
      locationCount: 62,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06161584',
      title: 'Real-World Safety and Treatment Patterns of Pegcetacoplan (Syfovre) in Geographic Atrophy',
      officialTitle: 'A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: null,
      conditions: ['Geographic Atrophy'],
      interventions: ['Pegcetacoplan'],
      sponsor: 'Apellis Pharmaceuticals, Inc.',
      startDate: '2023-09-28',
      completionDate: '2028-06',
      enrollment: 300,
      locationCount: 34,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT06961370',
      title: 'RO7669330 vs Pegcetacoplan (Syfovre) in Geographic Atrophy Secondary to AMD',
      officialTitle: 'A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD',
      status: 'RECRUITING',
      phase: 'Phase 1',
      conditions: ['Geographic Atrophy', 'Age-related Macular Degeneration'],
      interventions: ['RO7669330', 'Syfovre\u2122', 'Izervay\u2122'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2025-07-16',
      completionDate: '2027-01-03',
      enrollment: 132,
      locationCount: 16,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT05776472',
      title: 'Real World Effectiveness Study of Pegcetacoplan in Patients With PNH',
      officialTitle: 'A Single Arm, Long-term, Multicentre Observational Study to Evaluate Effectiveness of Pegcetacoplan Under Real World Conditions in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)',
      status: 'RECRUITING',
      phase: null,
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: ['Pegcetacoplan'],
      sponsor: 'Swedish Orphan Biovitrum',
      startDate: '2023-06-26',
      completionDate: '2029-08-15',
      enrollment: 200,
      locationCount: 75,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT05809531',
      title: 'Long-term Safety and Efficacy of Pegcetacoplan in C3 Glomerulopathy or IC-MPGN',
      officialTitle: 'An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['C3G', 'IC-MPGN', 'C3 Glomerulopathy', 'Dense Deposit Disease', 'Membranoproliferative Glomerulonephritis'],
      interventions: ['Pegcetacoplan'],
      sponsor: 'Apellis Pharmaceuticals, Inc.',
      startDate: '2023-05-29',
      completionDate: '2027-07',
      enrollment: 100,
      locationCount: 47,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT07214298',
      title: 'Pegcetacoplan + Modified FOLFIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma',
      officialTitle: 'A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma',
      status: 'RECRUITING',
      phase: 'Phase 1/Phase 2',
      conditions: ['Metastatic Pancreatic Ductal Adenocarcinoma'],
      interventions: ['Pegcetacoplan', 'Fluorouracil', 'Irinotecan', 'Leucovorin Calcium', 'Oxaliplatin'],
      sponsor: 'Roswell Park Cancer Institute',
      startDate: '2026-03-01',
      completionDate: '2028-10-01',
      enrollment: 35,
      locationCount: 1,
      studyType: 'INTERVENTIONAL',
    },
  ],

  // ---------------------------------------------------------------------------
  // Crovalimab (Roche/Chugai) — recycling anti-C5 antibody
  // ---------------------------------------------------------------------------
  crovalimab: [
    {
      nctId: 'NCT07172022',
      title: 'Crovalimab in People With Antiphospholipid Syndrome (APS)',
      officialTitle: 'A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating Efficacy, Safety, and Pharmacokinetics of Crovalimab in Patients With Antiphospholipid Syndrome (APS)',
      status: 'NOT_YET_RECRUITING',
      phase: 'Phase 2',
      conditions: ['Antiphospholipid Syndrome'],
      interventions: ['Crovalimab', 'Placebo', 'VKA'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2026-03-16',
      completionDate: '2030-12-02',
      enrollment: 300,
      locationCount: 0,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04432584',
      title: 'Crovalimab Versus Eculizumab in PNH Patients Currently Treated With Complement Inhibitors',
      officialTitle: 'A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: ['Crovalimab', 'Eculizumab'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2020-09-30',
      completionDate: '2027-09-30',
      enrollment: 190,
      locationCount: 81,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04654468',
      title: 'Crovalimab in PNH Patients Not Previously Treated With Complement Inhibition',
      officialTitle: 'A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: ['Crovalimab'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2021-03-17',
      completionDate: '2026-12-31',
      enrollment: 51,
      locationCount: 4,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT05075824',
      title: 'Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease',
      officialTitle: 'A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 2',
      conditions: ['Sickle Cell Disease'],
      interventions: ['Crovalimab', 'Placebo'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2022-03-09',
      completionDate: '2026-04-08',
      enrollment: 90,
      locationCount: 27,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT03157635',
      title: 'Crovalimab Phase I/II in Healthy Volunteers and PNH Patients',
      officialTitle: 'An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 1/Phase 2',
      conditions: ['Paroxysmal Hemoglobinuria, Nocturnal'],
      interventions: ['Crovalimab', 'Placebo'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2016-11-14',
      completionDate: '2026-09-30',
      enrollment: 59,
      locationCount: 14,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04958265',
      title: 'Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)',
      officialTitle: 'A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Atypical Hemolytic Uremic Syndrome'],
      interventions: ['Crovalimab'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2021-11-17',
      completionDate: '2029-05-19',
      enrollment: 41,
      locationCount: 22,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04434092',
      title: 'Crovalimab Versus Eculizumab in PNH Patients Not Previously Treated With Complement Inhibitors',
      officialTitle: 'A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
      interventions: ['Crovalimab', 'Eculizumab'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2020-10-08',
      completionDate: '2027-09-30',
      enrollment: 210,
      locationCount: 63,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04861259',
      title: 'Crovalimab in Adult and Adolescent Participants With aHUS',
      officialTitle: 'A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Atypical Hemolytic Uremic Syndrome'],
      interventions: ['Crovalimab'],
      sponsor: 'Hoffmann-La Roche',
      startDate: '2021-10-22',
      completionDate: '2029-08-20',
      enrollment: 83,
      locationCount: 43,
      studyType: 'INTERVENTIONAL',
    },
  ],

  // ---------------------------------------------------------------------------
  // Zilucoplan (UCB) — subcutaneous C5 peptide inhibitor
  // ---------------------------------------------------------------------------
  zilucoplan: [
    {
      nctId: 'NCT07215949',
      title: 'Zilucoplan for Severe gMG Exacerbations',
      officialTitle: 'Zilucoplan Treatment of Severe MG Exacerbations Leading to Hospitalization of Participants With Acetylcholine Receptor Antibody Positive gMG',
      status: 'RECRUITING',
      phase: 'Phase 3',
      conditions: ['Generalized Myasthenia Gravis (gMG)'],
      interventions: ['Zilucoplan\u00ae'],
      sponsor: 'Miriam Freimer',
      startDate: '2026-01-20',
      completionDate: '2028-04-01',
      enrollment: 15,
      locationCount: 1,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06055959',
      title: 'Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis',
      officialTitle: 'A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis',
      status: 'RECRUITING',
      phase: 'Phase 2/Phase 3',
      conditions: ['Generalized Myasthenia Gravis'],
      interventions: ['Zilucoplan'],
      sponsor: 'UCB Biopharma SRL',
      startDate: '2024-10-16',
      completionDate: '2026-12-25',
      enrollment: 8,
      locationCount: 9,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06435312',
      title: 'Open-label Extension Study of Zilucoplan in Pediatric Participants With gMG',
      officialTitle: 'An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis',
      status: 'ENROLLING_BY_INVITATION',
      phase: 'Phase 3',
      conditions: ['Generalized Myasthenia Gravis'],
      interventions: ['Zilucoplan'],
      sponsor: 'UCB Biopharma SRL',
      startDate: '2024-11-19',
      completionDate: '2027-11-19',
      enrollment: 8,
      locationCount: 8,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04225871',
      title: 'Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis',
      officialTitle: 'A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: 'Phase 3',
      conditions: ['Generalized Myasthenia Gravis'],
      interventions: ['zilucoplan (RA101495)'],
      sponsor: 'UCB Biopharma SRL',
      startDate: '2019-12-23',
      completionDate: '2026-06-02',
      enrollment: 200,
      locationCount: 70,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT04297683',
      title: 'HEALEY ALS Platform Trial - Master Protocol',
      officialTitle: 'HEALEY ALS Platform Trial',
      status: 'RECRUITING',
      phase: 'Phase 2/Phase 3',
      conditions: ['Amyotrophic Lateral Sclerosis'],
      interventions: ['Zilucoplan', 'Verdiperstat', 'CNM-Au8', 'Pridopidine', 'SLS-005 Trehalose', 'ABBV-CLS-7262', 'DNL343', 'NUZ-001'],
      sponsor: 'Merit E. Cudkowicz, MD',
      startDate: '2020-06-14',
      completionDate: '2028-08',
      enrollment: 1500,
      locationCount: 74,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06815133',
      title: 'Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis',
      officialTitle: 'Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients With Anti-AChR Myasthenia Gravis',
      status: 'RECRUITING',
      phase: null,
      conditions: ['Myasthenia Gravis'],
      interventions: ['Zilbrysq'],
      sponsor: 'Centre Hospitalier Universitaire de Nice',
      startDate: '2025-03-01',
      completionDate: '2026-03-03',
      enrollment: 55,
      locationCount: 1,
      studyType: 'OBSERVATIONAL',
    },
    {
      nctId: 'NCT06961747',
      title: 'Zilucoplan Concentration in Breast Milk of Healthy Lactating Women',
      officialTitle: 'An Open-Label, Repeated-Dose Assessment of Zilucoplan Concentration in Breast Milk of Healthy Lactating Women',
      status: 'RECRUITING',
      phase: 'Phase 1',
      conditions: ['Healthy Participants'],
      interventions: ['Zilucoplan'],
      sponsor: 'UCB Biopharma SRL',
      startDate: '2025-07-09',
      completionDate: '2026-07-22',
      enrollment: 15,
      locationCount: 2,
      studyType: 'INTERVENTIONAL',
    },
    {
      nctId: 'NCT06906692',
      title: 'Meningococcal Vaccination in Patients on Complement Inhibitors',
      officialTitle: 'Evaluation of Antibody Titles After Meningococcal Vaccination in Patients With Myasthenia Gravis and Neuromyelitis Optica Candidate to Complement Inhibitors Therapy',
      status: 'ACTIVE_NOT_RECRUITING',
      phase: null,
      conditions: ['Myasthenia Gravis Generalised', 'Vaccination', 'Complement System', 'Neuromyelitis Optica Spectrum Disease (NMOSD)'],
      interventions: ['Serum Bactericidal Assay'],
      sponsor: 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',
      startDate: '2025-03-25',
      completionDate: '2027-04-01',
      enrollment: 35,
      locationCount: 1,
      studyType: 'OBSERVATIONAL',
    },
  ],
};

// =============================================================================
// COMPLETED LANDMARK TRIALS
// =============================================================================
export const TRIALS_COMPLETED_LANDMARK = [
  // --- Ravulizumab + PNH completed trials ---
  {
    nctId: 'NCT05274633',
    title: 'Real Life Use of Ravulizumab in Italian Patients With PNH',
    officialTitle: 'Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study.',
    status: 'COMPLETED',
    phase: null,
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2022-06-17',
    completionDate: '2025-03-24',
    enrollment: 120,
    locationCount: 6,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT03748823',
    title: 'Ravulizumab SC Versus Ravulizumab IV in Adults With PNH Currently Treated With Eculizumab',
    officialTitle: 'A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizumab',
    status: 'COMPLETED',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Ravulizumab OBDS', 'Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2019-02-19',
    completionDate: '2023-08-31',
    enrollment: 139,
    locationCount: 51,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05630001',
    title: 'Iptacopan in PNH Patients on Stable Anti-C5 Who Switch to Iptacopan',
    officialTitle: 'A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb\u226510 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan',
    status: 'COMPLETED',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Iptacopan'],
    sponsor: 'Novartis Pharmaceuticals',
    startDate: '2023-04-24',
    completionDate: '2024-10-17',
    enrollment: 52,
    locationCount: 23,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05972967',
    title: 'OMS906 in PNH Patients With Sub-optimal Response to Ravulizumab',
    officialTitle: 'A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of OMS906 in PNH Patients With a Sub-optimal Response to the C5 Inhibitor, Ravulizumab',
    status: 'COMPLETED',
    phase: 'Phase 2',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['OMS906'],
    sponsor: 'Omeros Corporation',
    startDate: '2023-03-27',
    completionDate: '2024-10-10',
    enrollment: 12,
    locationCount: 5,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT03056040',
    title: 'ALXN1210 (Ravulizumab) Versus Eculizumab in Adult PNH Patients Currently Treated With Eculizumab',
    officialTitle: 'A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab',
    status: 'COMPLETED',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria (PNH)'],
    interventions: ['Ravulizumab', 'Eculizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2017-05-17',
    completionDate: '2022-02-21',
    enrollment: 202,
    locationCount: 51,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT04320602',
    title: 'Ravulizumab in Adult PNH Participants Currently Treated With High-Dose Eculizumab',
    officialTitle: 'Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab',
    status: 'COMPLETED',
    phase: 'Phase 4',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Eculizumab', 'Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2021-04-14',
    completionDate: '2022-12-20',
    enrollment: 18,
    locationCount: 4,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT02605993',
    title: 'Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in PNH Participants',
    officialTitle: 'A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria',
    status: 'COMPLETED',
    phase: 'Phase 2',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria', 'PNH'],
    interventions: ['Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2016-01-04',
    completionDate: '2022-01-12',
    enrollment: 26,
    locationCount: 16,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05842486',
    title: 'Hematological Response in PNH Patients Treated With Anti-C5 Antibody: External Control Arm for Iptacopan',
    officialTitle: 'Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 na\u00efve Patients',
    status: 'COMPLETED',
    phase: null,
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Anti-C5 antibody treatment'],
    sponsor: 'Assistance Publique - H\u00f4pitaux de Paris',
    startDate: '2023-01-18',
    completionDate: '2023-03-01',
    enrollment: 92,
    locationCount: 1,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT03406507',
    title: 'Ravulizumab (ALXN1210) in Children and Adolescents With PNH',
    officialTitle: 'A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)',
    status: 'COMPLETED',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria'],
    interventions: ['Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2018-02-22',
    completionDate: '2022-08-25',
    enrollment: 13,
    locationCount: 9,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT06577949',
    title: 'Ravulizumab in Chinese Adults With PNH',
    officialTitle: 'A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Na\u00efve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China',
    status: 'COMPLETED',
    phase: 'Phase 3',
    conditions: ['Paroxysmal Nocturnal Hemoglobinuria', 'PNH'],
    interventions: ['Ravulizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2024-10-10',
    completionDate: '2025-12-22',
    enrollment: 18,
    locationCount: 8,
    studyType: 'INTERVENTIONAL',
  },

  // --- Eculizumab + aHUS completed trials ---
  {
    nctId: 'NCT03518203',
    title: 'Eculizumab to Treat TMA/aHUS-Associated MODS in Hematopoietic Stem Cell Transplant Recipients',
    officialTitle: 'Early Intervention With Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome (TMA/aHUS)-Associated Multiple Organ Dysfunction Syndrome (MODS) in Hematopoietic Stem Cell Transplant (HCT) Recipients',
    status: 'COMPLETED',
    phase: 'Phase 2',
    conditions: ['Thrombotic Microangiopathies', 'Atypical Hemolytic Uremic Syndrome', 'Multiple Organ Dysfunction Syndrome'],
    interventions: ['Eculizumab'],
    sponsor: "Children's Hospital Medical Center, Cincinnati",
    startDate: '2018-08-03',
    completionDate: '2022-06-01',
    enrollment: 23,
    locationCount: 3,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT00844844',
    title: 'Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS',
    officialTitle: 'An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)',
    status: 'COMPLETED',
    phase: 'Phase 2',
    conditions: ['Atypical Hemolytic Uremic Syndrome'],
    interventions: ['Eculizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2009-05',
    completionDate: '2013-07',
    enrollment: 1,
    locationCount: 17,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT05876351',
    title: 'Eculizumab in Pediatric and Adult Participants With aHUS in China',
    officialTitle: 'Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment-Na\u00efve Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China',
    status: 'COMPLETED',
    phase: 'Phase 3',
    conditions: ['Atypical Hemolytic Uremic'],
    interventions: ['Eculizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2023-07-14',
    completionDate: '2025-05-07',
    enrollment: 25,
    locationCount: 6,
    studyType: 'INTERVENTIONAL',
  },
  {
    nctId: 'NCT01770951',
    title: 'Retrospective Observational Trial to Assess Eculizumab Treatment Effect in aHUS Patients',
    officialTitle: 'A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)',
    status: 'COMPLETED',
    phase: null,
    conditions: ['Atypical Hemolytic Uremic Syndrome (aHUS)'],
    interventions: [],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2009-08-31',
    completionDate: '2010-11-30',
    enrollment: 30,
    locationCount: 23,
    studyType: 'OBSERVATIONAL',
  },
  {
    nctId: 'NCT00844545',
    title: 'Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS',
    officialTitle: 'An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)',
    status: 'COMPLETED',
    phase: 'Phase 2',
    conditions: ['Atypical Hemolytic Uremic Syndrome'],
    interventions: ['Eculizumab'],
    sponsor: 'Alexion Pharmaceuticals, Inc.',
    startDate: '2009-05',
    completionDate: '2013-07',
    enrollment: 16,
    locationCount: 17,
    studyType: 'INTERVENTIONAL',
  },
];

// =============================================================================
// SUMMARY STATISTICS (computed from data above)
// =============================================================================
export const TRIAL_STATS = {
  fetchDate: '2026-02-23',
  source: 'ClinicalTrials.gov v2 API',
  counts: {
    solirisActive: TRIALS_SOLIRIS.length,
    ultomirisActive: TRIALS_ULTOMIRIS.length,
    iptacopanActive: 10,
    pegcetacoplanActive: 10,
    crovalimabActive: 8,
    zilucoplanActive: 8,
    completedLandmark: TRIALS_COMPLETED_LANDMARK.length,
  },
  get totalActive() {
    return this.counts.solirisActive + this.counts.ultomirisActive +
      this.counts.iptacopanActive + this.counts.pegcetacoplanActive +
      this.counts.crovalimabActive + this.counts.zilucoplanActive;
  },
};
